Amphastar Pharma (AMPH) Tops Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Amphastar Pharma (AMPH) Tops Q3 EPS by 5c

Amphastar Pharmaceuticals (AMPH) PT Raised to $17 at BMO Capital on 3Q Report; 'Awaiting Execution With Key Pipeline Opportunities'

November 10, 2017 9:29 AM EST

BMO Capital raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $17.00 (from $16.00) while maintaining a Market Perform rating, following the company's third quarter earnings report.

Analyst Gary Nachman notes an improved price targets, as the company reported third quarter earnings per share and... More

Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Jefferies

November 9, 2017 8:28 AM EST

Jefferies raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $19.00) while maintaining a Buy rating.

Analyst David Steinberg notes revenue for the quarter came in slightly above their estimates at $57.9M largely due to better than expected Naloxone... More

Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Piper Jaffray

November 9, 2017 7:52 AM EST

Piper Jaffray raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $19.00) while maintaining an Overweight rating.

Analyst David Amsellem notes solid performance from the base business. The analyst believes there is still room for meaningful value creation in the context of an EV/2018E EBITDA of 10x-11x.

... More